These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34149037)

  • 1. Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
    Hirko KA; Regan MM; Remolano MC; Schlossman J; Harrison B; Yeh E; Jacene H; Nakhlis F; Block C; Rosenbluth JM; Garrido-Castro AC; Overmoyer BA
    Am J Clin Oncol; 2021 Sep; 44(9):449-455. PubMed ID: 34149037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermal lymphatic invasion and inflammatory breast cancer are independent predictors of outcome after postmastectomy radiation.
    Abramowitz MC; Li T; Morrow M; Sigurdson ER; Anderson P; Nicolaou N; Freedman G
    Am J Clin Oncol; 2009 Feb; 32(1):30-3. PubMed ID: 19194121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
    Lacerda L; Reddy JP; Liu D; Larson R; Li L; Masuda H; Brewer T; Debeb BG; Xu W; Hortobágyi GN; Buchholz TA; Ueno NT; Woodward WA
    Stem Cells Transl Med; 2014 Jul; 3(7):849-56. PubMed ID: 24833589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
    Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
    Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying factors that impact survival among women with inflammatory breast cancer.
    Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
    Ann Oncol; 2012 Apr; 23(4):870-5. PubMed ID: 21765048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
    Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory Breast Cancer at the Extremes of Age.
    Adesoye T; Babayemi O; Postlewait LM; DeSnyder SM; Sun SX; Woodward WA; Ueno NT; Hunt KK; Lucci A; Teshome M
    Ann Surg Oncol; 2021 Oct; 28(10):5626-5634. PubMed ID: 34292426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases.
    Hoffman HJ; Khan A; Ajmera KM; Zolfaghari L; Schenfeld JR; Levine PH
    Am J Clin Oncol; 2014 Aug; 37(4):315-21. PubMed ID: 23241503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
    Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
    BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer.
    Gruber G; Ciriolo M; Altermatt HJ; Aebi S; Berclaz G; Greiner RH
    Int J Cancer; 2004 Mar; 109(1):144-8. PubMed ID: 14735481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.
    Parrish KM; Thomas SM; Cartwright SB; van den Bruele AB; Zasloff R; DiLalla GA; DiNome ML; Menendez CS; Rosenberger LH; Woriax HE; Hwang ES; Plichta JK; Chiba A
    Ann Surg Oncol; 2024 Nov; 31(12):8057-8067. PubMed ID: 39158638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction.
    Raghav K; French JT; Ueno NT; Lei X; Krishnamurthy S; Reuben JM; Valero V; Ibrahim NK
    PLoS One; 2016; 11(1):e0145534. PubMed ID: 26752563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
    Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
    Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of and survival following brain metastases among women with inflammatory breast cancer.
    Dawood S; Ueno NT; Valero V; Andreopoulou E; Hsu L; Lara J; Woodward W; Buchholz TA; Hortobagyi GN; Cristofanilli M
    Ann Oncol; 2010 Dec; 21(12):2348-2355. PubMed ID: 20439340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.
    Kai M; Kogawa T; Liu DD; Fouad TM; Kai K; Niikura N; Hsu L; Willey JS; Theriault RL; Valero V; Ueno NT
    Clin Breast Cancer; 2015 Feb; 15(1):37-42. PubMed ID: 25258308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
    Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
    Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
    Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
    Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
    Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.